Phase II/III multicenter, randomized, double-blind, placebo-controlled trial on acetyl-L-carnitine (ALCAR) in subjects living with amyotrophic lateral sclerosis (ALS). Primary study aim: The clinical objective consists of assessing the efficacy of ALCAR (two different dosages will be tested: 1.5g/day and 3g/day) on the progression of functional disability (loss of self-sufficiency), as measured by the ALSFRS-R scale. Secondary study aims: 1. The effect of ALCAR treatment on different clinical aspects: functional decline as measured by ALSFRS-R total score; the decline of forced vital capacity (FVC); quality of life as measured by ALSAQ-40 scale; cognitive function as measured by Edinburgh Cognitive and Behavioural ALS Screen (ECAS) scale; survival (being alive and without tracheostomy). 2. To measure the effects of ALCAR treatment on disease biomarkers potentially involved in the drug's mechanisms of action. These include PGC-1 alpha, 3-nitrotyrosine (3-NT), acetyl cyclophilin A (acetyl-PPIA), neurofilament light chain (NFL), creatine kinase (CK), Musclin/osteocrin, MyomiRNA (MiR-206), Uric acid, Matrix metalloproteinase-9 (MMP-9), Monocyte Chemoattractant Protein-1 (MCP-1), 4-Hydroxynonenal (HNE). 3. The tolerability and safety of ALCAR treatment by identifying unexpected adverse events.
Study population: 246 subjects will be enrolled on one Australian and ten Italian ALS sites.
Inclusion criteria: subjects aged 18+ years with a diagnosis of ALS according to Gold Coast Criteria; disease duration <24 months; satisfactory bulbar and spinal function (self-sufficiency evaluated by a score 3+ on the ALSFRS-R for swallowing, cutting food and handling utensils, and walking); satisfactory respiratory function (FVC ≥80% of predicted); documented progression of symptoms as measured by the ALSFRS-R scale. Disease progression rate (DFS) must be>= 0.33. DFS =(48- ALSFRS-R at screening)/months from onset to screening, treatment with Riluzole in the last four weeks. Exclusion criteria: antecedent polio infection; other motor neuron disease; involvement of other systems possibly determining a functional impairment; other severe clinical conditions; unwillingness or inability to take riluzole; previous use of ALCAR for any reason; inability to understand and comply with the study requirements, and to give written informed consent personally or via their legally authorized representative.
All eligible participants will be randomized to receive ALCAR (1,5 or 3 g/day) or placebo in addition to riluzole 50 mg b.i.d. Permuted block (with a block size of 6), 1:1:1 centralized randomization scheme will be used. The overall treatment duration will be 48 weeks. After enrolment, each participant will be followed up until death. Eligible subjects will be seen after 4, 12, 24, 36 and 48 weeks. At each visit, a general assessment will be made, including vital signs, body mass index (BMI), neurological examination (including quantitative and qualitative evaluation of the motor system), comorbidity, concomitant treatments and adverse events. Blood samples will be collected at baseline -Day 1 (randomization)-, 4, 12, 24, 36 and 48 weeks to test biomarkers. Functional disability will be assessed at each visit using the ALS-FRS-R scale. The respiratory function will be assessed using a spirometer to measure FVC before starting treatment (baseline visit) and at 4, 12, 24, 36 and 48 weeks. Cognitive function will be evaluated at baseline, weeks 24 and 48, using ECAS scale. Health-related quality of life, measured by the ALSAQ-40, will be tested at baseline, 24 and 48 weeks. Compliance will be tested by the local investigators, counting unused packages at each follow-up visit. Pre-planned statistical analyses will be done on Intention-to-treat and Per-protocol (PP) populations. The statistical plan will include descriptive statistics and a comparison of the proportions of self-sufficient participants at week 48 using the chi-square or Fisher's exact test for the primary endpoint. Secondary endpoints measured by numerical scores obtained from clinical scales will be analyzed using repeated measures mixed models, while biomarkers using repeated measures ANOVA. Time-to-event endpoints, such as survival and the probability of remaining self-sufficient over 48 weeks, will be analyzed with Kaplan-Meier curves. The number of adverse events and serious adverse events after 48 weeks will be compared between treatment arms.

Start Date01 Oct 2024

Sponsor / Collaborator

Fightmnd

[+1]

CTRI/2024/07/070353 / Not yet recruitingPhase 3IIT

ACETYL-L-CARNITINE as augmentation therapyin Clozapine resistant Schizophrenia - NIL

Start Date20 Jul 2024

Sponsor / Collaborator-

NCT05355311 / Not yet recruitingPhase 1IIT

Acetyl-L-carnitine Supplementation for Co-occurring Depression and Alcohol Use Disorder in Adolescents: A Randomized Placebo-Controlled Pilot Study

The primary objective of this study is to evaluate the effects of acetyl-L-carnitine (ALCAR), 3 g daily, and matched placebo on alcohol cue-elicited alcohol craving during a human laboratory paradigm after 4 weeks of daily dosing among participants ages 14-20 with alcohol use disorder (AUD) as confirmed by the Diagnostic and Statistical Manual of Mental Disorders - Fifth Edition (DSM-5™) and who report at least mild depressive symptoms on the Beck Depression Inventory-II. Secondary objectives include evaluation of ALCAR (3g/day) and matched placebo on alcohol craving and use, subjective effects of alcohol consumption, mood, sleep, alcohol use negative consequences, study retention, and safety and tolerability.

Start Date01 Jun 2023

Sponsor / Collaborator

Brown University

[+3]

100 Clinical Results associated with Acetyl-L-carnitine

100 Translational Medicine associated with Acetyl-L-carnitine

100 Patents (Medical) associated with Acetyl-L-carnitine

2,153

Literatures (Medical) associated with Acetyl-L-carnitine

01 Oct 2024·Water Research

Revealing degradation pathways of soluble and dissolved organic matter in alluvial-lacustrine aquifer systems impacted by high levels of geogenic ammonium

Article

Author: Wang, Yanxin ; Du, Yao ; Gan, Yiqun ; Shi, Huanhuan ; Deng, Yamin ; Liu, Meihui ; Xiong, Yaojin

The excessive presence of geogenic ammonium (NH₄⁺) in groundwater poses a global environmental concern, commonly linked to the degradation of nitrogen-containing dissolved organic matter (DOM). However, there is a gap in systematic studies on the combination of soluble organic matter (SOM) in sediments and DOM in groundwater, with few indoor incubation experiments to validate their degradation pathways. This study utilized ultrahigh-resolution Fourier transform ion cyclotron resonance mass spectrometry to analyze the molecular characteristics of DOM and SOM in aquifer systems affected by geogenic NH₄⁺. Subsequently, indoor incubation experiments spanning up to 140 d were conducted to verify the degradation pathways. The experimental results revealed a two-phase degradation process for both the DOM and SOM. The initial stage was characterized by the degradation of aliphatic compounds (ALC) with the production of polyphenols (PPE) and highly unsaturated compounds (HUC). The second stage was dominated by the degradation of PPE and HUC, accompanied by the re-consumption of some ALC, while more recalcitrant HUC persisted. Notably, the first stage of SOM degradation exceeded that of DOM degradation, indicating that SOM exhibited greater resistance to aging. This phenomenon may be attributed to a wider range of active enzymes in sediments, the rapid replenishment of SOM by organic matter in sediments, or the accelerated degradation of DOM. The experimental results aligned with the molecular characterization of DOM and SOM in actual aquifer systems. It is hypothesized that NH₄⁺ produced through the direct mineralization of SOM may contribute more to the enrichment of NH₄⁺ in groundwater than that produced through the mineralization of DOM. This study is the first to analyze DOM and SOM together in aquifer systems and validate their degradation pathways through incubation experiments, thereby providing novel insights into the enrichment of geogenic NH₄⁺ in groundwater.

01 Oct 2024·Neuroscience

Acetyl-l-carnitine alleviates valproate-induced autism-like behaviors through attenuation of hippocampal mitochondrial dysregulation

Article

Author: Sadr, Seyed Shahabeddin ; Hosseini, Marjan ; Sanaeierad, Ashkan ; Roghani, Mehrdad ; Zahedi, Elham

01 Oct 2024·Pain and Therapy

Neuronutritional Approach to Fibromyalgia Management: A Narrative Review

Review

Author: Vorobyeva, Yulia ; Lepshina, Mariia ; Kosareva, Anastasiia ; Novikov, Viacheslav ; Danilov, Alexey ; Danilov, Andrey ; Badaeva, Anastasiia

Fibromyalgia (FM) is a complex and common syndrome characterized by chronic widespread pain, fatigue, sleep disturbances, and various functional symptoms without clear structural or pathological causes. Affecting approximately 1-5% of the global population, with a higher prevalence in women, FM significantly impacts patients' quality of life, often leading to considerable healthcare costs and loss of productivity. Despite its prevalence, the etiology of FM remains elusive, with genetic, environmental, and psychological factors, including nutrition, being implicated. Currently, no universally accepted treatment guidelines exist, and management strategies are often symptomatic. This narrative review explores the potential of a neuronutritional approach to FM management. It synthesizes existing research on the relationship between FM and nutrition, suggesting that dietary interventions could be a promising complementary treatment strategy. Various nutritional interventions, including vitamin D, magnesium, iron, and probiotics supplementation, have shown potential in reducing FM symptoms, such as chronic pain, anxiety, depression, cognitive dysfunction, sleep disturbances, and gastrointestinal issues. Additionally, weight loss has been associated with reduced inflammation and improved quality of life in FM patients. The review highlights the anti-inflammatory benefits of plant-based diets and the low-FODMAPs diet, which have shown promise in managing FM symptoms and related gastrointestinal disorders. Supplements such as vitamin D, magnesium, vitamin B12, coenzyme Q10, probiotics, omega-3 fatty acids, melatonin, S-adenosylmethionine, and acetyl-L-carnitine are discussed for their potential benefits in FM management through various mechanisms, including anti-inflammatory effects, modulation of neurotransmitters, and improvement of mitochondrial function. In conclusion, this review underscores the importance of considering neuronutrition as a holistic approach to FM treatment, advocating for further research and clinical trials to establish comprehensive dietary guidelines and to optimize management strategies for FM patients.

News (Medical) associated with Acetyl-L-carnitine

06 Feb 2024

·www.prnewswire.com

Recognize National Senior Independence Month by Supporting Your Vitality With Gundry MD Energy Renew

A Dietary Supplement That Helps Recharge Your Energy and Fight Visible Signs of Aging LOS ANGELES, Feb. 6, 2024 /PRNewswire/ -- February is National Senior Independence Month. It is dedicated to empowering our senior community with the tools and knowledge to achieve well-being and vitality. Dr. Steven Gundry, a cardiothoracic surgeon and renowned expert in health and nutrition, provides invaluable tips to help maintain independence and vitality at any age. Continue Reading Gundry MD Energy Renew is a dietary supplement crafted with the delightful flavors of passionfruit and hibiscus. This specially crafted supplement is designed to help bolster your body's cell vitality, enabling the generation of energy. Formulated with the finest ingredients, including an exclusive polyphenol blend, Gundry MD Energy Renew cannot only support healthy energy levels but also help promote sustained wakefulness and mental clarity, aiding in your daily recovery. Navigating the natural changes that come with aging, like pains and decreased energy, can be challenging. But, Dr. Gundry teaches that aging does not have to equate to this. His motto is to help people 'die young at a ripe old age.' Dr. Gundry emphasizes three key tips to support longevity and vitality: Exercise Snacking: Incorporating short bursts of physical activity throughout the day, or as he likes to call it, "exercise snacking" Exercise snacking is a powerful way to boost energy levels and enhance overall well-being. Simple, quick exercises can make a significant difference in maintaining mobility and vitality, such as doing squats while brushing your teeth, dancing in your living room to an entire song, or leg or calf raises while you're watching TV Gut-Buddy Friendly Diet: Dr. Gundry advocates for a diet that feeds your good gut bacteria and starves the bad bacteria. Eat foods with soluble fiber, like asparagus and pressure-cooked beans. Incorporate fermented foods, like sauerkraut and sugar-free coconut yogurt, daily. And avoid sugary, highly processed foods. Take Supplements: To further support your energy levels and vitality, Dr. Gundry recommends using Gundry MD Energy Renew. This unique supplement features a robust blend of superfruits and hibiscus, combined with D-Ribose and Acetyl L-Carnitine. These ingredients work synergistically to support your energy stores and combat the unpleasant discomfort that comes with aging.†* Energy Renew also boasts a distinctive blend of superfruit extracts, delivering a mega-boost of polyphenols. These compounds act as powerful antioxidants and help "rewind the clock" and offer support to tired, aging cells. By incorporating Gundry MD Energy Renew into your daily routine, you can take proactive steps towards maintaining independence and embracing the joys of aging with vitality.†* What is Gundry MD Energy Renew? Gundry MD Energy Renew is a passion fruit-flavored dietary supplement designed to unleash the benefits of its unique blend of ingredients, promoting youthful energy and vitality. This powerful formula includes superfruits and hibiscus, coupled with D-Ribose and Acetyl L-Carnitine, working harmoniously to help boost cellular energy without the risk of crashing. Within Gundry MD Energy Renew, superfruits flood your body with antioxidants, supporting the immune system and facilitating easier weight management. Meanwhile, the combination of D-Ribose and Acetyl L-Carnitine enhances alertness throughout the day, promoting a youthful feeling and contributing to healthy-looking skin. This well-balanced blend of potent energy boosters and superfruits serves as an ideal pick-me-up for those grappling with exhaustion, weakness, or premature visible aging. Gundry MD Energy Renew also features healthy compounds capable of virtually support aging cells. This unique aspect of the supplement can help foster independence and mobility as you age, making it a comprehensive solution for your overall well-being.†* Where to Purchase Gundry MD Energy Renew Gundry MD Energy Renew can be purchased on the Gundry MD website for the cost of $74.95 for a 30-day supply with a 90-day purchase price guarantee. Suggested Use of Gundry MD Energy Renew Gundry MD Energy Renew can be effortlessly prepared by mixing one scoop of the passionfruit-hibiscus flavored powder with 8 oz. of water. You can incorporate this supplement into your routine at any time of day. Simply mix, sip, and experience the revitalizing benefits of Gundry MD Energy Renew. About Gundry MD Founded in 2015, Gundry MD is dedicated to providing cutting-edge solutions to its users by using science-backed ingredients that can offer a boost in metabolism, all-day energy, smooth, easy digestion, and a youthful-feeling mind and body. These amazing results all begin with feeding your body powerful health-boosting nutrients like polyphenols. Based on his many years of nutrition research, Dr. Gundry helps create every Gundry MD product. Best-selling Gundry MD products include Total Restore, Energy Renew, and Polyphenol-Rich Olive Oil. All Gundry MD products come with a 90-day purchase price guarantee if you are not satisfied. For more information, visit or @gundrymd on Instagram and Facebook.† About Dr. Gundry Founder of Gundry MD, Dr. Steven Gundry was one of the world's top cardiothoracic surgeons and is currently the medical director at The International Heart and Lung Institute and The Centers for Restorative Medicine in Palm Springs, Beverly Hills, and Santa Barbara, California. He has spent the past 25 years helping people restore their health by optimizing nutrition and lifestyle choices. Steven Gundry, MD is also the host of the top-ranked health podcast, The Dr. Gundry Podcast, and author of four New York Times best-selling books including The Plant Paradox™ which details his famous lectin-free Plant Paradox Diet. His new book Gut Check provides the keys to unlocking our gut health, allowing our bodies, and their microbiome, to function at their highest potential. For more information, visit drgundry.com and the Dr. Gundry YouTube channel, and follow @drstevengundry on Instagram and TikTok. *All individuals are unique. Your results can and will vary. Media Contact: Ashley Beenen [email protected] SOURCE Gundry MD

03 Apr 2023

·www.biospace.com

CPI-818 Data Highlights Potential for ITK Inhibition as a New Immunotherapy Approach for the Treatment of T Cell Lymphoma

Interim data from Phase 1/1b clinical trial of CPI-818, including new evidence supporting the recently implemented minimum absolute lymphocyte count (ALC) predictive biomarker Data presented at the 10th Whistler Global Summit on Hematologic Malignancies BURLINGAME, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced interim data demonstrating the potential of CPI-818, the Company’s ITK inhibitor, for the treatment of T cell lymphoma (TCL) at the 10th Whistler Global Summit on Hematologic Malignancies, which took place March 29 to April 2, 2023 in Whistler British Columbia, Canada. The CPI-818 data was presented by John Reneau, MD, PhD, from The Ohio State University Comprehensive Cancer Center. Dr. Reneau is a hematologist who specializes in treating patients with lymphoma and an investigator for the Phase 1/1b clinical trial of CPI-818 for TCL. “T cell lymphoma is a challenging disease to treat and there is significant need for new approaches given the limited efficacy of current therapeutic options,” said Dr. Reneau. “CPI-818 has a novel mechanism of action that includes the stimulation of normal T cells to infiltrate and destroy tumors. Our recent work indicates that the peripheral blood absolute lymphocyte count is a biomarker that may predict patients most likely to benefit from CPI-818. This positions our trial to build on the results CPI-818 has already demonstrated - monotherapy activity in advanced, relapsed patients, with potential for higher response rates driven by this new biomarker.” CPI-818 Phase 1/1b T Cell Lymphoma Data CPI-818 is currently being studied in a Phase 1/1b clinical trial as a single agent therapy in patients with relapsed TCL. As of February 23, 2023, 20 patients were enrolled in the 200 mg cohort (optimal dose), including 13 evaluable for tumor response. There have been 1 complete response (CR) of 24 months duration, 1 equivocal CR awaiting confirmatory PET scan of 13+ months duration (a previous partial response (PR)), 1 nodal CR of 21 months duration and 1 PR of 7 months duration. Ten patients continue on therapy, including seven who have not yet been evaluated for tumor response. Corvus has identified minimum absolute lymphocyte count (ALC) above 900 per cubic milliliter of blood as a biomarker associated with response to CPI-818. Interim data from the 200 mg cohort in the Phase 1/1b clinical trial indicate that this minimum ALC level is required for tumor response and disease control. As of February 23, 2023, four of eight patients with ALC above 900 had objective responses (those four patients are described above), all eight had disease control (stable disease, PR, CR) and the median progression free survival (PFS) was 28.1 months. No objective responses were seen in five patients (0 of 5) with ALC below 900 and the PFS was 2.1 months. New interim data, as of February 23, 2023, presented by Dr. Reneau evaluated the effect of ALC on PFS of patients based on their last prior chemotherapy treatment before receiving CPI-818. There was no significant difference in the PFS achieved in patients with ALC less than 900 per cubic milliliter (PFS = 3.2 months) compared to patients with ALC greater than or equal to 900 per cubic milliliter (PFS = 3.4 months), which suggests the ALC biomarker is not predictive for standard therapies. This result is consistent with CPI-818’s proposed mechanism of action, which involves the enhancement of normal lymphocyte function, and indicates that the improved results seen with CPI-818 in patients with ALC above 900 is not due to more favorable patient characteristics. The swimmer and waterfall tumor plots for these patients, along with the data summarizing the ALC biomarker data, are included in Dr. Reneau’s presentation slides, which are available on the Publications and Presentations page of the Corvus website. “The data from our Phase 1/1b trial of CPI-818 for T cell lymphoma continues to be strong, with durable and deep tumor responses observed to date,” said Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus. “We are encouraged that enrollment has accelerated and that we have implemented a biomarker that we believe will enable us to enroll patients most likely to benefit from CPI-818, which is of particular importance as we plan for a registration Phase 3 randomized clinical trial. I want to thank Dr. Reneau and all our investigators for their participation in the trial and for the work they do in support of patients.” About Corvus Pharmaceuticals Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company. Corvus’ lead product candidate is CPI-818, an investigational, oral, small molecule drug that selectively inhibited ITK in preclinical studies and is in a multicenter Phase 1/1b clinical trial in patients with several types of T cell lymphomas. The Company’s second clinical program, ciforadenant (CPI-444), is an oral, small molecule inhibitor of the A2A receptor that is in an open-label Phase 1b/2 clinical trial. Its third clinical program, mupadolimab (CPI-006), is a humanized monoclonal antibody directed against CD73 that has exhibited immunomodulatory activity and activation of immune cells in preclinical and clinical studies. For more information, visit . About CPI-818 CPI-818 is an investigational small molecule drug given orally that has selectively inhibited ITK (interleukin-2-inducible T cell kinase) in preclinical studies. It was designed to block malignant T cell growth and to modulate immune responses. ITK, an enzyme, is expressed predominantly in T cells and plays a role in T cell and natural killer (NK) cell lymphomas and leukemias, as well as in normal immune function. Recent clinical data in T cell lymphomas suggests that CPI-818 has the potential to control differentiation of T helper cells and enhance immune responses to tumors. Interference with ITK signaling also can modulate immune responses to various antigens. Optimal doses of CPI-818 have been shown to affect T cell differentiation and induce the generation of Th1 helper cells while blocking the development of both Th2 and Th17 cells and production of Th2 related cytokines. Th1 T cells are required for immunity to tumors, viral infections and other infectious diseases. Th2 and Th17 helper T cells are involved in the pathogenesis of many autoimmune and allergic diseases. The immunologic effects of CPI-818 lead to what is known as Th1 skewing and is made possible by the high selectivity of CPI-818 for ITK. The Company believes the inhibition of specific molecular targets in T cells may be of therapeutic benefit for patients with T cell lymphomas, solid tumors, and in patients with autoimmune and allergic diseases. The Company is conducting a Phase 1/1b trial in patients with refractory T cell lymphomas that was designed to select the optimal dose of CPI-818 and evaluate its safety, PK, target occupancy, immunologic effects, biomarkers and efficacy. Interim data from the Phase 1/1b clinical trial of CPI-818 for T cell lymphoma demonstrated tumor responses in very advanced, refractory, difficult to treat T cell malignancies, and identified a dose that maximally affects T helper cell differentiation. Forward-Looking Statements This press release contains forward-looking statements, including statements related to the potential safety and efficacy of CPI-818, ciforadenant and mupadolimab; the Company’s ability to develop and advance product candidates into and successfully complete preclinical studies and clinical trials, including the Company Phase 1/1b clinical trial of CPI-818 and the Company’s planned Phase 3 registration clinical trial with CPI-818 for T cell lymphoma; the design of clinical trials, including the target number of patients to be enrolled and whether identifying certain biomarkers will help accelerate enrollment; and the timing of the availability and announcement of clinical data and certain other product development milestones. All statements other than statements of historical fact contained in this press release are forward-looking statements. These statements often include words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “seek,” “will,” “may” or similar expressions. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company’s control. The Company’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 28, 2023, as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: the Company’s ability to demonstrate sufficient evidence of efficacy and safety in its clinical trials of CPI-818, ciforadenant and mupadolimab; the accuracy of the Company’s estimates relating to its ability to initiate and/or complete preclinical studies and clinical trials; the results of preclinical studies and interim data from clinical trials not being predictive of future results; the unpredictability of the regulatory process; regulatory developments in the United States, and other foreign countries; the costs of clinical trials may exceed expectations; and the Company’s ability to raise additional capital. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the events and circumstances reflected in the forward-looking statements will be achieved or occur, and the timing of events and circumstances and actual results could differ materially from those projected in the forward-looking statements. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. INVESTOR CONTACT: Leiv Lea Chief Financial Officer Corvus Pharmaceuticals, Inc. +1-650-900-4522 llea@corvuspharma.com MEDIA CONTACT: Sheryl Seapy Real Chemistry +1-949-903-4750 sseapy@realchemistry.com

ImmunotherapyClinical ResultPhase 3Phase 1

28 Oct 2022

·www.prnewswire.com

Gundry MD Energy Renew Celebrates Selling Over 1 Million Units

LOS ANGELES, Oct. 28, 2022 /PRNewswire/ -- Gundry MDTM Energy Renew celebrates 1+ million units sold. Crafted by world-renowned medical researcher and cardiothoracic surgeon, Dr. Steven Gundry, this powerful supplement helps support energy and vitality. As we age, we can often experience a decrease in energy, due to our body slowing down. Gundry MD Energy Renew works to combat this issue by supporting metabolic health. What is Gundry MD Energy Renew? Continue Reading Gundry MD Energy Renew is a Powerful Dietary Supplement That Helps Promote a Youthful Energy and Vitality While Supporting Metabolism Gundry MD Energy Renew is a tasty dietary supplement that was crafted with high-quality ingredients, including a proprietary polyphenol blend designed to promote an all-day wakefulness and a clear mind. Made with a tasty passionfruit and hibiscus flavor, Gundry MD Energy Renew also contains several potent ingredients that help support the re-energization of the body to combat issues associated with aging. However, having more physical and mental energy is just one of the benefits Gundry MD Energy Renew provides. Additional benefits can include an improvement in the appearance of skin and metabolism support. Meanwhile, Gundry MD Energy Renew also works to help your body fight harmful free radicals that can accelerate aging.†* Gundry MD Energy Renew Ingredients D-Ribose (Bioenergy Ribose®) N-Acetyl L-Carnitine Betta Berries™ Polyphenol Blend: Beet, Hibiscus Flower Extract, Acai, Acerola, Amla, Jabuticaba, Cranberry, Goji, Mangosteen, Maqui Berry, Pomegranate, Strawberry, and Schisandra Berry Key Benefits of Gundry MD Energy Renew†* Promotes wakefulness and clearer thinking Supports a healthy metabolism Aids faster recovery from day-to-day activities Helps your body defend against harmful free radicals *All individuals are unique. Your results can and will vary. Where to Buy Gundry MD Energy Renew Gundry MD Energy Renew can be purchased on the Gundry MD site for $74.95 for a 30-day supply with a 90-day refund guarantee. †These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. About Gundry MD Founded in 2015, Gundry MD is dedicated to providing cutting-edge solutions to its users by using science-backed ingredients that can offer a boost in metabolism, all-day energy, smooth, easy digestion, and a youthful-feeling mind and body. These amazing results all begin with feeding your body powerful health-boosting nutrients like polyphenols. Based on his many years of research on nutrition, Dr. Gundry helps create every Gundry MD product. Best-selling Gundry MD products include Total Restore, Bio Complete 3, and Polyphenol-Rich Olive Oil. All Gundry MD products come with a 90-day money-back guarantee if you are not satisfied. For more information, visit or @gundrymd on Instagram and Facebook. About Dr. Gundry Founder of Gundry MD, Dr. Steven Gundry is a pioneer in nutrition and one of the world's top cardiothoracic surgeons, as well as medical director at The International Heart and Lung Institute and The Centers for Restorative Medicine in Palm Springs and Santa Barbara, California. He has spent the past 20 years helping people restore their health by optimizing nutrition and lifestyle choices. Steven Gundry, MD is also the host of the health podcast, The Dr. Gundry Podcast, and author of four New York Times best-selling books including The Plant Paradox ™ which details his famous lectin-free or Plant Paradox Diet. Since his first Paradox book release, Dr. Gundry has been in the media spotlight, interviewed by Goop, MindBodyGreen, New York Times, Morning Joe and so many more outlets. Dr. Gundry's newest book, Unlocking the Keto Code is now available for purchase. For more information, visit . Press contact: Dana Lewis [email protected] SOURCE Gundry MD

100 Deals associated with Acetyl-L-carnitine

External Link

KEGG	Wiki	ATC	Drug Bank
-	Acetyl-L-carnitine	N06BX12	DB08842

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetic Neuropathies	IT	Sigma-Tau Industrie Farmaceutiche Riunite SpA	23 Feb 1995
Alzheimer Disease	IT	Sigma-Tau Industrie Farmaceutiche Riunite SpA	28 Jan 1995
Peripheral Nervous System Diseases	-	-	-

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Breast Cancer	Phase 2	US	Alfasigma SpA	01 Mar 2007
Amyotrophic Lateral Sclerosis	Phase 2	US	Leadiant Biosciences, Inc.	-
Diabetes Complications	Phase 2	JP	Mitsubishi Tanabe Pharma Corp.	-
Diabetic Neuropathies	Phase 2	US	GSK Plc	-
Fatigue	Phase 2	US	Sigma-Tau Industrie Farmaceutiche Riunite SpA	-
Optic Atrophy, Hereditary, Leber	Phase 2	US	Leadiant Biosciences, Inc.	-
Peripheral Nervous System Diseases	Phase 2	CN	Sigma-Tau Industrie Farmaceutiche Riunite SpA	-
Diabetes Mellitus, Type 2	Discovery	IT	Leadiant Biosciences, Inc.	01 Apr 2008
Hypertension	Discovery	IT	Leadiant Biosciences, Inc.	01 Apr 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


Tandem Meetings ASTCT and CIBMTR2023	Not Applicable	Metabolism, Inborn Errors absolute lymphocyte count	27	rATG dosing based on bodyweight and ALC	pldhkrpcge(umivcroonk) = fbpekunorf chjsykmpqf (bljqrazwdh ) View more	Positive	01 Feb 2023
NCT01695317 (EUDRACT (2012-001624-36) \| ALCAR, CTgov)	Phase 4	Migraine Disorders	72	Acetyl-L-carnitine (Acetyl-L-carnitine)	(pwgoqtkrer) = ifuhvfidvk ljtbxsusug (jsavgwxntp, rgroibyabi - oqjhcpuloy) View more	-	13 Apr 2022
				Acetyl-L-carnitine (Sugar Pills)	(pwgoqtkrer) = kgayyamcmg ljtbxsusug (jsavgwxntp, cozpzlwvei - heqmfqwbcy) View more
NCT01054768 (CTgov)	Phase 2	Inflammation \| Anemia, Sickle Cell	37	alpha-lipoic acid+acetyl-L-carnitine (Alpha-lipoic Acid and Acetyl-L-carnitine)	(jjmjpgrfzc) = ejfecybnip iqcwolmzjz (cjbawgzgfi, lzmjckuzbk - thhuzrumal) View more	-	03 Aug 2021
				Control (Placebo)	(jjmjpgrfzc) = yrpvhlcnlu iqcwolmzjz (cjbawgzgfi, nhnxlmgniw - ghzlffwvxj) View more
NCT05601479 (Pubmed \| Exp Ther Med)	Phase 2	Peripheral Nervous System Diseases	239	Acetyl-L-carnitine	(eoudcapjza) = ejumlvmmxd gsbaceeuds (pqvdfchehg )	Positive	01 Dec 2016
				Placebo	(eoudcapjza) = apksbpsizl gsbaceeuds (pqvdfchehg )
NCT02485158 (TDS, CTgov)	Not Applicable	-	28	placebo+amphetamine+THC (AMP Arm)	vntxeucxbl(fsjuyhtotr) = wakskmfnlg bonjmytgwc (stiembigtk, bsnafolysn - nvxxrnjwtg) View more	-	29 Nov 2016
				placebo+THC (ALC Arm)	vntxeucxbl(fsjuyhtotr) = zzsajfmopd bonjmytgwc (stiembigtk, ujouonsttd - zzdispteat) View more
NCT01695317 (EUDRACT (2012-001624-36), Pubmed \| Cephalalgia)	Phase 4	Migraine Disorders	72	Acetyl-l-carnitine	(svdyygecju) = whjowbjqgn mfzikxnres (sfbznjrdxe )	Negative	01 Oct 2015
				Placebo	(svdyygecju) = fqksohrkta mfzikxnres (sfbznjrdxe )
ECTRIMS2013	Not Applicable	Multiple Sclerosis	-	Amantadine 200 mg	(zqjqtadgrs) = xiehspegze xorteushvy (ozkqsbvpcm )	Positive	30 Sep 2013
				Acetyl L carnitine 2g	(zqjqtadgrs) = ptkqggclaw xorteushvy (ozkqsbvpcm )
NCT00719706 (CTgov)	Phase 2	Bipolar Disorder	40	alpha-lipoic acid+acetyl-l-carnitine (ALCAR/ALA)	wqqhsaiyfu(dxbixpthfo) = msdiijiqqr gblujklhwl (ogndvjbujk, fdivwoolek - votfgalbma) View more	-	18 Jul 2012
				placebo (Placebo)	wqqhsaiyfu(dxbixpthfo) = uezwolglmy gblujklhwl (ogndvjbujk, xhilpkghhl - jfcjqhvjjn) View more
P04.151 (AAN2012)	Not Applicable	Amyotrophic Lateral Sclerosis	-	Acetyl-L-Carnitine 3g/day + Riluzole 100mg/day	dplbmrdnje(gtcdeqerez) = nqflznfcio lmksqvrpzw (dvitdclvfn ) View more	Positive	23 Apr 2012
				Placebo + Riluzole 100mg/day	dplbmrdnje(gtcdeqerez) = amzfvtyvjo lmksqvrpzw (dvitdclvfn ) View more
NCT00592488 (ALC, CTgov)	Phase 1/2	Shock, Septic	13	Acetyl-L-Carnitine (ALC) (Acetyl-L-Carnitine (ALC) Then Placebo)	(fownedkqkt) = olkclchagh zbuobuvfgv (vptlptfqqi, eivllzkyui - wuipyabebz)	-	08 Jun 2011
				Placebo (Placebo Then Acetyl-L-Carnitine (ALC))	(fownedkqkt) = sfjzdasske zbuobuvfgv (vptlptfqqi, ncwqtzqgmg - ksztugslbd)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis